These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 9735415)
1. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Gazitt Y; Rothenberg ML; Hilsenbeck SG; Fey V; Thomas C; Montegomrey W Int J Oncol; 1998 Oct; 13(4):839-48. PubMed ID: 9735415 [TBL] [Abstract][Full Text] [Related]
2. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Gazitt Y; Fey V; Thomas C; Alvarez R Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139 [TBL] [Abstract][Full Text] [Related]
3. In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. Ricotti L; Tesei A; De Paola F; Ulivi P; Frassineti GL; Milandri C; Amadori D; Zoli W Clin Cancer Res; 2003 Feb; 9(2):900-5. PubMed ID: 12576465 [TBL] [Abstract][Full Text] [Related]
4. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Jazirehi AR; Bonavida B Mol Cancer Ther; 2004 Jan; 3(1):71-84. PubMed ID: 14749477 [TBL] [Abstract][Full Text] [Related]
5. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Galmarini CM; Clarke ML; Falette N; Puisieux A; Mackey JR; Dumontet C Int J Cancer; 2002 Feb; 97(4):439-45. PubMed ID: 11802204 [TBL] [Abstract][Full Text] [Related]
6. Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Liu Q; Gazitt Y Blood; 2003 May; 101(10):4105-14. PubMed ID: 12521996 [TBL] [Abstract][Full Text] [Related]
7. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity. Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501 [TBL] [Abstract][Full Text] [Related]
8. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980 [TBL] [Abstract][Full Text] [Related]
10. Taxol can induce phosphorylation of BCL-2 in multiple myeloma cells and potentiate dexamethasone-induced apoptosis. Kroning R; Lichtenstein A Leuk Res; 1998 Mar; 22(3):275-86. PubMed ID: 9619919 [TBL] [Abstract][Full Text] [Related]
11. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352 [TBL] [Abstract][Full Text] [Related]
12. Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells. Liu ZJ; Xu W; Han J; Liu QY; Gao LF; Wang XH; Li XL Anticancer Drugs; 2020 Aug; 31(7):684-692. PubMed ID: 32282368 [TBL] [Abstract][Full Text] [Related]
13. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Ma J; Murphy M; O'Dwyer PJ; Berman E; Reed K; Gallo JM Biochem Pharmacol; 2002 Apr; 63(7):1219-28. PubMed ID: 11960598 [TBL] [Abstract][Full Text] [Related]
14. [Development and characterization of a gemcitabine-resistant variant of human lung adenocarcinoma cell line A549]. Dong M; Lin C; Feng FY; Zhang XY; Fu M; Liang X; Lu HY; Zha YY; Wu M Ai Zheng; 2004 Jun; 23(6):667-71. PubMed ID: 15191667 [TBL] [Abstract][Full Text] [Related]
15. Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer. Kielb SJ; Shah NL; Rubin MA; Sanda MG J Urol; 2001 Aug; 166(2):482-7. PubMed ID: 11458051 [TBL] [Abstract][Full Text] [Related]
16. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs. Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646 [TBL] [Abstract][Full Text] [Related]
17. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression. Wang M; Lu X; Dong X; Hao F; Liu Z; Ni G; Chen D World J Surg Oncol; 2015 Feb; 13():66. PubMed ID: 25880226 [TBL] [Abstract][Full Text] [Related]
18. Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells. Tan G; Heqing L; Jiangbo C; Ming J; Yanhong M; Xianghe L; Hong S; Li G Int J Cancer; 2002 Jan; 97(2):168-72. PubMed ID: 11774260 [TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Zhu K; Gerbino E; Beaupre DM; Mackley PA; Muro-Cacho C; Beam C; Hamilton AD; Lichtenheld MG; Kerr WG; Dalton W; Alsina M; Sebti SM Blood; 2005 Jun; 105(12):4759-66. PubMed ID: 15728126 [TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor BLU promotes paclitaxel antitumor activity by inducing apoptosis through the down-regulation of Bcl-2 expression in tumorigenesis. Park ST; Byun HJ; Kim BR; Dong SM; Park SH; Jang PR; Rho SB Biochem Biophys Res Commun; 2013 May; 435(1):153-9. PubMed ID: 23628417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]